The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N06 | Psychoanaleptics | |
3 | N06B | Psychostimulants, agents used for ADHD and nootropics | |
4 | N06BA | Centrally acting sympathomimetics |
Code | Title | |
---|---|---|
N06BA01 | Amfetamine | |
N06BA02 | Dexamfetamine | |
N06BA03 | Metamfetamine | |
N06BA04 | Methylphenidate | |
N06BA05 | Pemoline | |
N06BA06 | Fencamfamin | |
N06BA07 | Modafinil | |
N06BA08 | Fenozolone | |
N06BA09 | Atomoxetine | |
N06BA10 | Fenetylline | |
N06BA11 | ||
N06BA12 | ||
N06BA13 | ||
N06BA14 | ||
N06BA15 |
Active Ingredient | Description | |
---|---|---|
Amfetamine |
Amphetamine is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers, levoamphetamine and dextroamphetamine, in their pure amine forms. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. |
|
Armodafinil |
Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil (R-modafinil) has pharmacological properties similar to those of modafinil (a mixture of R- and S-modafinil), to the extent tested in animal and in vitro studies. |
|
Atomoxetine |
Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters. |
|
Dexamfetamine |
Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. |
|
Dexmethylphenidate |
Dexmethylphenidate is a CNS stimulant. It is the more pharmacologically active d-enantiomer of racemic methylphenidate. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. |
|
Fencamfamin |
|
|
Fenetylline |
|
|
Lisdexamfetamine |
Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine, which is responsible for the drug’s activity. Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. |
|
Metamfetamine |
Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. |
|
Methylphenidate |
Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. |
|
Modafinil |
Modafinil promotes wakefulness in a variety of species, including man. The precise mechanism(s) through which modafinil promotes wakefulness is unknown. |
|
Pemoline |
|
|
Solriamfetol |
Solriamfetol is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its mechanism of action has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine (noradrenaline) reuptake inhibitor (DNRI). |
Title | Information Source | Document Type | |
---|---|---|---|
ADDERALL XR Extended-release capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
AMFEXA Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CONCERTA Extended-release tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
CONTRAMYL Prolonged release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
DELMOSART Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DEXEDRINE SPANSULE Extended-release capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
ELVANSE Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
EQUASYM Modified release capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FOCALIN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
INIR Capsule | Health Products Regulatory Authority (ZA) | MPI, Generic | |
MATORIDE XR Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MEDIKINET Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
NUVIGIL Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
PROVIGIL Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RADD Prolonged-release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
RITALIN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RUBIFEN Immediate release tablet, Sustained release tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
STRATTERA Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SUNOSI Filmโcoated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
VYVANSE Capsule / Tablet chewable | FDA, National Drug Code (US) | MPI, US: SPL/PLR |